Jefferies initiates Teradyne coverage at Buy with a $284 target
Jefferies expects the testing-equipment market to grow from about $9 billion in 2025 to $25 billion by 2030, and sees Teradyne gaining system-on-chip share through dual sourcing at Nvidia and cloud companies. It also forecast Nvidia-related testing revenue could exceed $2 billion annually by 2029, compared with about $50 million in 2026.
Teradyne reports third-quarter revenue of $1.31 billion and guides for $1.25 billion to $1.35 billion
Teradyne’s third-quarter revenue increased 70% year over year to $1.31 billion, while non-GAAP earnings per share of $2.29 beat consensus. Semiconductor Test revenue exceeded $1 billion, and Robotics revenue reached a record $96 million and returned to profitability. The company’s fourth-quarter revenue guidance was $1.25 billion to $1.35 billion.
Teradyne launches Omnyx Edge board-test platform for physical and edge AI
Teradyne introduced Omnyx Edge, a platform for testing intelligence, sensing, and motion boards in robots, vehicles, and industrial systems. It adds boundary scan, touchless power sensing, LED testing, factory automation, and AI-based preventive maintenance. The company planned to demonstrate the platform at electronica 2026.
ARKK sells its remaining Teradyne shares for about $1.5 million
The sales completed ARKK’s disposal of its Teradyne shares, while ARKQ retained 231,809 shares. The transactions were negligible relative to Teradyne’s $41.49 billion market value, and ARK gave no reason. Teradyne had reported third-quarter revenue above $1.3 billion, up 70%, and forecast fourth-quarter revenue of $1.25 billion to $1.35 billion.
Simply Wall St says Teradyne shares are broadly in line with estimated value
Teradyne shares had risen about 194% in three years to roughly $265.78 amid optimism about AI chip and high-bandwidth memory testing. A discounted cash flow analysis based on trailing free cash flow of about $995 million and projected growth through 2030 suggested the shares were broadly in line with estimated intrinsic value. The article contrasted this with an analyst-consensus narrative seeing 37% upside.
Zacks upgrades Teradyne to Strong Buy as earnings estimates rise
Teradyne was upgraded to Zacks Rank #1 (Strong Buy) as analysts raised earnings estimates. The consensus estimate for fiscal 2026 increased 3.3% over the past three months to $9.41 per share. Zacks said the upgrade reflected improving earnings expectations and may support near-term share-price gains.
Teradyne invests $300 million in FormFactor and partners on testing
The partnership targets testing for increasingly complex AI chips, high-bandwidth memory, and optical components. FormFactor reported 40% year-over-year quarterly revenue growth but faced capacity constraints as it approached the limits of its current factories. Its new Farmers Branch facility had shipped its first production unit, and Teradyne’s investment may help fund expansion.
Zacks cites rising earnings estimates as Teradyne shares fall
Analysts expected current-quarter EPS of $2.11 and revenue of $1.31 billion, with fiscal-year EPS and sales estimates of $9.41 and $5.2 billion. Recent estimates had risen, and Teradyne had beaten earnings and revenue expectations in each of the previous four quarters. Zacks said the stock’s valuation received a D, indicating a premium to peers.
Teradyne Robotics partners with Sereact on automated logistics systems
The technology is already operating at European logistics hubs serving Zalando, and the companies recently presented a joint demonstration. The deal supports Teradyne’s effort to grow robotics as a second business alongside semiconductor test, though higher research and sales spending makes profitable, sustained adoption uncertain. Investors can monitor robotics revenue, Universal Robots shipments, and expansion of Zalando and CEVA deployments through 2027.
UBS cuts Teradyne price target to $430 and maintains Buy rating
Teradyne shares fell 17% in a week despite third-quarter revenue rising 70% to $1.306 billion and adjusted EPS beating estimates. Fourth-quarter revenue guidance is roughly flat sequentially, prompting concerns that AI-related test demand may be peaking. The analysis says UBS’s $430 target requires a higher valuation multiple or stronger earnings than currently forecast.